Dar Bioscience Inc (DARE) - News Archive

Dar Bioscience Inc.: A New Frontier in Smart Drug Delivery and Contraception Amidst Industry Challenges In an era where innovation and strategic partnerships drive the healthcare sector, Dar Bioscience Inc. has emerged...

Dar Bioscience Pushes Boundaries in Sexual Health with New Findings on Sildenafil Cream from Phase 2b RESPOND Study In a significant development for sexual health and female sexual dysfunction treatment, Dar Bioscience,...

In a groundbreaking announcement, Dar Bioscience has unveiled its plans for a Phase 3 clinical trial for Sildenafil Cream, 3.6%, aimed at treating Female Sexual Arousal Disorder (FSAD). This condition, often compared to...

The highly anticipated news has finally arrived! Dar Bioscience Inc., renowned for its groundbreaking pharmaceutical research and development, recently announced that its shares will begin trading on a split-adjusted ba...

Female Sexual Arousal Disorder (FSAD) is a common condition characterized by persistent or recurrent inability to attain or maintain sexual arousal, leading to distress and difficulties in intimate relationships. Despit...

Dar Bioscience, a renowned pharmaceutical company specializing in women s health, has recently announced a significant achievement in securing a whopping $22 million in non-dilutive strategic royalty financing. This fre...

Dar Biosciences, a renowned biotechnology company, has recently made waves in the medical community with its groundbreaking DARE-LARC1 platform technology. This innovative technology has not only shown promising results...

Dar Bioscience, a leading biotechnology company focused on women s health, has recently announced the publication of positive efficacy and safety findings from a pre-pivotal postcoital test study of Ovaprene, their inno...

Dare Bioscience: Advancements in Women s Health and Treatment OptionsDare Bioscience, a leading healthcare company focused on women s health, recently made significant strides in their ongoing research and development e...

The gap in the healthcare industry concerning the treatment of Female Sexual Arousal Disorder (FSAD) is glaringly wide with no FDA-approved treatment for the condition, leaving a significant population of women globally...

DARE Biosciences Breakthrough Technology Opens New Doors for Women s Health and BeyondIn an exciting development, DARE Biosciences revolutionary DARE-LARC1 platform technology has achieved proof-of-concept for a transfo...

Dare Bioscience, a leading pharmaceutical company, recently announced positive topline pharmacokinetic and exploratory efficacy results from the DARE-PDM1 Phase 1 clinical study. These results support the continued clin...

Dar Bioscience Inc, a leading pharmaceutical company, is developing a groundbreaking treatment called DARE-PTB1 to mitigate the risk of preterm birth. Currently, there are no FDA-approved treatment options available for...

Dyspareunia, a distressing symptom of vulvar and vaginal atrophy (VVA) associated with menopause, affects the quality of life for millions of women worldwide. While hormone therapy has traditionally been the go-to treat...

In a groundbreaking development for women s reproductive health, Dar Bioscience has announced the commencement of Phase 3 clinical trials for its investigational hormone-free monthly intravaginal contraceptive, Ovaprene...